Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity
2004-01-01 Frontini, L; Ardizzoia, A; Pressiani, T; Colombo, I; Simonelli, M; Vaghi, M; Lissoni, P; Gardani, G
Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control
2014-01-01 Simonelli, M; Denlinger, Cs; Goff, Lw; Noberasco, C; Kim, Ty; Thomas, Mb; De Braud, Fg; Zucali, Pa; Santoro, A; English, Pa; Gallo-Stampino, C; Wang, Ej; Carpentieri, M; Williams, Ja
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC)
2010-01-01 Zucali, P; Santoro, A; Rodriguez-Lope, C; Simonelli, M; Camacho, Lh; Senzer, Nn; Bolondi, L; Lamar, M; Abbadessa, G; Schwartz, Be
Vinorelbine as Second or Third-Line Therapy in Pemetrexed-Pretreated Malignant Pleural Mesothelioma (MPM) Patients
2015-01-01 Ceresoli, Gl; Zucali, Pa; Grosso, F; Mencoboni, M; Bonomi, P; Parra, Hjms; Pasello, G; Cortinovis, D; Perrino, M; Muzio, A; Bruzzone, A; De Vincenzo, F; Degiovanni, D; Simonelli, M; Beretta, Gd; Giordano, L; Santoro, A
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS
2010-01-01 Zucali, Pa; Santoro, A; Simonelli, M; De Vincenzo, F; Lorenzi, E; Rimassa, L; Balzarini, L; Quagliuolo, V; Lambiase, A; Bordignon, C
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF
2013-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Santoro, A; Lambiase, A; Bordignon, C
Tivantinib in combination with gemcitabine shows strong antitumor activity on mesothelioma cell lines and cytoskeletal effects via inhibition of actin
2014-01-01 Simonelli, M; Zucali, R; Suter, M; Rubino, L; Santoro, A; Carlo-Stella, C
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
2015-01-01 Ott, Pa; Piha-Paul, Sa; Munster, P; Pishvaian, Mj; Van Brummelen, E; Cohen, R; Gomez-Roca, C; Ejadi, S; Stein, M; Chan, E; Simonelli, M; Morosky, A; Yuan, Ss; Koshiji, M; Bennouna, J
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF
2012-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Santoro, A; Lambiase, A; Bordignon, C
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients
2015-01-01 Ceresoli, Gl; Zucali, Pa; Grosso, F; Mencoboni, M; Sauta, Mg; Parra, Hjs; Pasello, G; Cortinovis, D; Perrino, M; Muzio, A; Bruzzone, A; De Vincenzo, F; Degiovanni, D; Bonomi, M; Simonelli, M; Beretta, Gd; Giordano, L; Santoro, A
Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study
2010-01-01 De Vincenzo, F; Zucali, P; Ceresoli, G; Gianoncelli, L; Lorenzi, E; Simonelli, M; Ripa, C; Giordano, L; Santoro, A
MODULATION OF IL-2 CANCER IMMUNOTHERAPY BY CYCLOOXYGENASE (COX)-2 INHIBITORS: THERAPEUTIC AND BIOLOGICAL RESULTS OF IL-2 PLUS CELECOXIB IN METASTATIC RENAL CELL CANCER (RCC) PROGRESSING ON IL-2 ALONE
2004-01-01 Lissoni, P; Vaghi, M; Frontini, L; Ardizzoia, A; Pressiani, T; Colombo, I; Simonelli, M; Gardani, G
The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin
2009-01-01 Zucali, P; Destro, A; Ceresoli, Gl; Gianoncelli, L; Lorenzi, E; De Vincenzo, F; Simonelli, M; Giordano, L; Roncalli, M; Santoro, A
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery
2014-01-01 Lopci, E; Bello, L; Olivari, L; Raneri, F; Simonelli, M; Riva, M; Navarria, P; Zucali, Pa; Colombo, P; Scorsetti, M; Santoro, A; Chiti, A
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC)
2013-01-01 Simonelli, M; Zucali, Pa; Thomas, Mb; Brisendine, A; Berlin, J; Noberasco, C; Denlinger, Cs; Kim, Ty; Santoro, A; Gallo-Stampino, C; Carpentieri, M; Wang, Ej; Williams, Ja; De Braud, Fg
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S)
2012-01-01 Simonelli, M; Zucali, Pa; Lorenzi, E; Rubino, L; De Vincenzo, F; Perrino, M; Rimassa, L; Giordano, L; Santoro, A
Phase Lib trial of tivantinib in combination with carboplatin and pernetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesotheliorna (MPM)
2014-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Fatuzzo, G; Bertossl, M; Suter, Mb; Perrino, M; Giordano, L; Santoro, A
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours
2011-01-01 Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mg; Zuradelli, M; Giordano, L; Santoro, A
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
2015-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Fatuzzo, G; Bertossi, M; Perrino, M; Miggiano, C; Giordano, L; Bonifacio, C; Sposta, Fm; Santoro, A
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy
2006-01-01 Banna, Gl; Gulio, G; Masci, G; Simonelli, M; Rimassa, L; Di Tommaso, L; Bettio, D; Roncalli, M; Santoro, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity | 1-gen-2004 | Frontini, L; Ardizzoia, A; Pressiani, T; Colombo, I; Simonelli, M; Vaghi, M; Lissoni, P; Gardani, G | |
| Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control | 1-gen-2014 | Simonelli, M; Denlinger, Cs; Goff, Lw; Noberasco, C; Kim, Ty; Thomas, Mb; De Braud, Fg; Zucali, Pa; Santoro, A; English, Pa; Gallo-Stampino, C; Wang, Ej; Carpentieri, M; Williams, Ja | |
| Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) | 1-gen-2010 | Zucali, P; Santoro, A; Rodriguez-Lope, C; Simonelli, M; Camacho, Lh; Senzer, Nn; Bolondi, L; Lamar, M; Abbadessa, G; Schwartz, Be | |
| Vinorelbine as Second or Third-Line Therapy in Pemetrexed-Pretreated Malignant Pleural Mesothelioma (MPM) Patients | 1-gen-2015 | Ceresoli, Gl; Zucali, Pa; Grosso, F; Mencoboni, M; Bonomi, P; Parra, Hjms; Pasello, G; Cortinovis, D; Perrino, M; Muzio, A; Bruzzone, A; De Vincenzo, F; Degiovanni, D; Simonelli, M; Beretta, Gd; Giordano, L; Santoro, A | |
| PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS | 1-gen-2010 | Zucali, Pa; Santoro, A; Simonelli, M; De Vincenzo, F; Lorenzi, E; Rimassa, L; Balzarini, L; Quagliuolo, V; Lambiase, A; Bordignon, C | |
| Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF | 1-gen-2013 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Santoro, A; Lambiase, A; Bordignon, C | |
| Tivantinib in combination with gemcitabine shows strong antitumor activity on mesothelioma cell lines and cytoskeletal effects via inhibition of actin | 1-gen-2014 | Simonelli, M; Zucali, R; Suter, M; Rubino, L; Santoro, A; Carlo-Stella, C | |
| Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 | 1-gen-2015 | Ott, Pa; Piha-Paul, Sa; Munster, P; Pishvaian, Mj; Van Brummelen, E; Cohen, R; Gomez-Roca, C; Ejadi, S; Stein, M; Chan, E; Simonelli, M; Morosky, A; Yuan, Ss; Koshiji, M; Bennouna, J | |
| IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF | 1-gen-2012 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Santoro, A; Lambiase, A; Bordignon, C | |
| Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients | 1-gen-2015 | Ceresoli, Gl; Zucali, Pa; Grosso, F; Mencoboni, M; Sauta, Mg; Parra, Hjs; Pasello, G; Cortinovis, D; Perrino, M; Muzio, A; Bruzzone, A; De Vincenzo, F; Degiovanni, D; Bonomi, M; Simonelli, M; Beretta, Gd; Giordano, L; Santoro, A | |
| Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study | 1-gen-2010 | De Vincenzo, F; Zucali, P; Ceresoli, G; Gianoncelli, L; Lorenzi, E; Simonelli, M; Ripa, C; Giordano, L; Santoro, A | |
| MODULATION OF IL-2 CANCER IMMUNOTHERAPY BY CYCLOOXYGENASE (COX)-2 INHIBITORS: THERAPEUTIC AND BIOLOGICAL RESULTS OF IL-2 PLUS CELECOXIB IN METASTATIC RENAL CELL CANCER (RCC) PROGRESSING ON IL-2 ALONE | 1-gen-2004 | Lissoni, P; Vaghi, M; Frontini, L; Ardizzoia, A; Pressiani, T; Colombo, I; Simonelli, M; Gardani, G | |
| The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin | 1-gen-2009 | Zucali, P; Destro, A; Ceresoli, Gl; Gianoncelli, L; Lorenzi, E; De Vincenzo, F; Simonelli, M; Giordano, L; Roncalli, M; Santoro, A | |
| Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery | 1-gen-2014 | Lopci, E; Bello, L; Olivari, L; Raneri, F; Simonelli, M; Riva, M; Navarria, P; Zucali, Pa; Colombo, P; Scorsetti, M; Santoro, A; Chiti, A | |
| Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) | 1-gen-2013 | Simonelli, M; Zucali, Pa; Thomas, Mb; Brisendine, A; Berlin, J; Noberasco, C; Denlinger, Cs; Kim, Ty; Santoro, A; Gallo-Stampino, C; Carpentieri, M; Wang, Ej; Williams, Ja; De Braud, Fg | |
| Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) | 1-gen-2012 | Simonelli, M; Zucali, Pa; Lorenzi, E; Rubino, L; De Vincenzo, F; Perrino, M; Rimassa, L; Giordano, L; Santoro, A | |
| Phase Lib trial of tivantinib in combination with carboplatin and pernetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesotheliorna (MPM) | 1-gen-2014 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Fatuzzo, G; Bertossl, M; Suter, Mb; Perrino, M; Giordano, L; Santoro, A | |
| Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours | 1-gen-2011 | Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mg; Zuradelli, M; Giordano, L; Santoro, A | |
| Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial | 1-gen-2015 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Fatuzzo, G; Bertossi, M; Perrino, M; Miggiano, C; Giordano, L; Bonifacio, C; Sposta, Fm; Santoro, A | |
| Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy | 1-gen-2006 | Banna, Gl; Gulio, G; Masci, G; Simonelli, M; Rimassa, L; Di Tommaso, L; Bettio, D; Roncalli, M; Santoro, A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 4 Contributo in Atti di Convegno ...990
Data di pubblicazione
- 2020 - 202321
- 2010 - 2019515
- 2000 - 2009348
- 1990 - 199980
- 1980 - 198926
Editore
- s.n110
- sn21
- Società Italiana di Fisiologia7
- Monduzzi Editore5
- Springer5
- AMER SOC CLINICAL ONCOLOGY, 2318 ...3
- COFESE EDIZIONI PALERMO3
- Hungarian Society of Sport Science2
- IMECHE2
- ISAKOS2
Rivista
- ANNALS OF ONCOLOGY27
- JOURNAL OF CLINICAL ONCOLOGY22
- GASTROENTEROLOGY20
- EUROPEAN JOURNAL OF CANCER13
- JOURNAL OF CROHN'S AND COLITIS10
- KNEE SURGERY, SPORTS TRAUMATOLOGY...10
- NEURO-ONCOLOGY10
- EUROPEAN RESPIRATORY JOURNAL SUPP...8
- INTERNATIONAL JOURNAL OF GYNECOLO...7
- CANCER RESEARCH6
Serie
- IEEE ENGINEERING IN MEDICINE AND ...1
Keyword
- acl reconstruction11
- pneumonia8
- follow-up4
- knee4
- navigation system4
- ACL RECONSTRUCTION3
- CPAP3
- double bundle3
- failure3
- lca3
Lingua
- eng486
- ita173
- fre7
- und3
Accesso al fulltext
- no fulltext963
- reserved27